First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2047-2994
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens ; volume:9 ; number:1 ; day:26 ; month:8 ; year:2020 ; pages:1-6 ; date:12.2020
Antimicrobial resistance and infection control ; 9, Heft 1 (26.8.2020), 1-6, 12.2020
- Urheber
-
Fokam, Joseph
Takou, Desire
Semengue, Ezechiel Ngoufack Jagni
Teto, Georges
Beloumou, Grace
Dambaya, Beatrice
Santoro, Maria-Mercedes
Mossiang, Leonella
Billong, Serge Clotaire
Cham, Fatim
Sosso, Samuel Martin
Temgoua, Edith Saounde
Nanfack, Aubin Joseph
Moudourou, Sylvie
Kamgaing, Nelly
Kamgaing, Rachel
Ngako Pamen, Joelle Nounouce
Etame, Mireille Mpoudi Ngole
Bissek, Anne-Cecile Z.-K
Elat, Jean-Bosco N.
Moussi, Emmanuel Eben
Colizzi, Vittorio
Perno, Carlo-Federico
Ndjolo, Alexis
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13756-020-00799-2
- URN
-
urn:nbn:de:101:1-2020101419065445384749
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fokam, Joseph
- Takou, Desire
- Semengue, Ezechiel Ngoufack Jagni
- Teto, Georges
- Beloumou, Grace
- Dambaya, Beatrice
- Santoro, Maria-Mercedes
- Mossiang, Leonella
- Billong, Serge Clotaire
- Cham, Fatim
- Sosso, Samuel Martin
- Temgoua, Edith Saounde
- Nanfack, Aubin Joseph
- Moudourou, Sylvie
- Kamgaing, Nelly
- Kamgaing, Rachel
- Ngako Pamen, Joelle Nounouce
- Etame, Mireille Mpoudi Ngole
- Bissek, Anne-Cecile Z.-K
- Elat, Jean-Bosco N.
- Moussi, Emmanuel Eben
- Colizzi, Vittorio
- Perno, Carlo-Federico
- Ndjolo, Alexis
- SpringerLink (Online service)
Ähnliche Objekte (12)
Modifying dolutegravir to PrEPare for long life
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Modifying dolutegravir to PrEPare for long life
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
Dolutegravir (HIV-Infektion) : Nutzenbewertung gemäß § 35a SGB V
Modifying dolutegravir to PrEPare for long life
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
Dolutegravir: Nutzenbewertung gemäß § 35a SGB V
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
Creation of a long-acting nanoformulated dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi
Dolutegravir/Abacavir/ Lamivudin: Nutzenbewertung gemäß § 35a SGB V
Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment